Vanda Pharmaceuticals Inc. (VNDA) is a publicly traded company in the Unknown sector. Across all available filings, 57 corporate insiders have executed 870 transactions totaling $331.6M, demonstrating a bearish sentiment with -$293.2M in net insider flow. The most recent transaction on Feb 18, 2026 involved a transaction of 525,000 shares valued at $0.
No significant insider buying has been recorded for VNDA in the recent period.
No significant insider selling has been recorded for VNDA in the recent period.
Based on recent SEC filings, insider sentiment for VNDA is bearish with an Insider Alignment Score of 6/100 and a net flow of -$293.2M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Vanda Pharmaceuticals Inc. (VNDA) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 57 insiders are actively trading VNDA stock, having executed 870 transactions in the past 90 days. The most active insider is David Russ Ramsay (Executive), who has made 38 transactions totaling $73.3M.
Get notified when executives and directors at VNDA file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Feb 18, 2026 | Hristos Polymeropoulos Mihael | Executive | Award | 525,000 | $N/A | $0 | |
| Feb 18, 2026 | Patrick Moran Kevin | SVP, CFO & Treasurer | Award | 125,000 | $N/A | $0 | C-Suite |
| Feb 18, 2026 | Williams Timothy | SVP & General Counsel | Award | 125,000 | $N/A | $0 | |
| Feb 18, 2026 | Birznieks Gunther | SVP, Business Development | Award | 125,000 | $N/A | $0 | |
| Feb 18, 2026 | Wijkstrom Joakim | SVP, Chief Marketing Officer | Award | 125,000 | $N/A | $0 | |
| Aug 7, 2025 | Hristos Polymeropoulos Mihael | Executive | Purchase | 10,000 | $4.15 | $41.5K | |
| Jul 29, 2024 | Patrick Moran Kevin | Executive | Sale | 2,251 | $5.92 | $13.3K | |
| May 22, 2024 | Chrousos Phaedra | Executive | Award | 21,887 | $N/A | $0 | |
| May 17, 2024 | Sempowski Ward Anne | Executive | Award | 20,529 | $N/A | $0 | |
| May 17, 2024 | Ray Mitchell Stephen | Executive | Award | 20,529 | $N/A | $0 | |
| May 17, 2024 | W. Dugan Richard | Executive | Award | 20,529 | $N/A | $0 | |
| May 17, 2024 | Honore Tage | Executive | Award | 20,529 | $N/A | $0 | |
| Mar 5, 2024 | Birznieks Gunther | Executive | Sale | 8,684 | $4.13 | $35.9K | |
| Mar 5, 2024 | Patrick Moran Kevin | Executive | Sale | 8,902 | $4.20 | $37.4K | |
| Mar 5, 2024 | Hristos Polymeropoulos Mihael | Executive | Sale | 24,288 | $4.13 | $100.3K |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 475 | $312.4M | 90.4% |
Purchase(P) | 56 | $19.2M | 5.6% |
Exercise(M) | 168 | $13.0M | 3.8% |
Payment(F) | 6 | $773.0K | 0.2% |
Award(A) | 89 | $48.7K | 0.0% |
Gift(G) | 4 | $0 | 0.0% |
Other(J) | 34 | $0 | 0.0% |
Conversion(C) | 38 | $0 | 0.0% |
Insider selling pressure at Vanda Pharmaceuticals Inc. has increased, with 57 insiders executing 870 transactions across all time. Total sales of $312.4M significantly outpace purchases of $19.2M, resulting in a net outflow of $293.2M. This selling activity appears largely discretionary, which may warrant closer attention from investors.